Description of Collaborative Activity: |
An NIMH Program Officer (PO) was invited to serve as a voting ad hoc member of one of the FDA Arthritis Drugs Advisory Committees, which met to review a new drug application for the treatment of Chronic Fatigue Syndrome (CFS). Subsequently, the NIMH PO has been invited as the sole NIH representative to a follow-up meeting planned at the FDA among FDA staff, a CDC representative, and the sponsor to discuss further steps in Myalgic Encephalomyelitis/CFS drug development. |
